Daniel Couto Net Worth

The estimated Net Worth of Daniel Couto is at least $76.1 Thousand dollars as of 3 November 2015. Daniel Couto owns over 2,867 units of ContraFect Corp stock worth over $666 and over the last 10 years Daniel sold CFRX stock worth over $75,392.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Daniel Couto CFRX stock SEC Form 4 insiders trading

Daniel has made over 6 trades of the ContraFect Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently Daniel sold 2,872 units of CFRX stock worth $10,942 on 17 November 2015.

The largest trade Daniel's ever made was selling 2,872 units of ContraFect Corp stock on 17 November 2015 worth over $10,942. On average, Daniel trades about 1,721 units every 7 days since 2014. As of 3 November 2015 Daniel still owns at least 2,872 units of ContraFect Corp stock.

You can see the complete history of Daniel Couto stock trades at the bottom of the page.

What's Daniel Couto's mailing address?

Daniel's mailing address filed with the SEC is 61 BACON HILL ROAD, , PLEASANTVILLE, NY, 10510.

Insiders trading at ContraFect Corp

Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz, and Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.

What does ContraFect Corp do?

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba

Complete history of Daniel Couto stock trades at ContraFect Corp

ContraFect Corp executives and stock owners

ContraFect Corp executives and other stock owners filed with the SEC include:

• Roger Pomerantz,
  Chairman of the Board, Chief Executive Officer
• Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.,
  Chairman, CEO & Pres
• Dr. Roger James Pomerantz FACP, M.D., F.A.C.P.,
  Chairman, CEO & Pres
• Cara Cassino,
  Executive Vice President - Research and Development, Chief Medical Officer
• Dr. Cara M. Cassino,
  Chief Medical Officer and Exec. VP of R&D
• Natalie Bogdanos,
  General Counsel, Corporate Secretary
• Michael Messinger CPA, CPA,
  Chief Financial Officer
• Michael Messinger,
  Chief Financial Officer
• Nancy Dong,
  Vice President - Finance and Administration
• Sol Barer,
  Lead Independent Director
• David Low,
  Independent Director
• Michael Otto,
  Independent Director
• Cary Sucoff,
  Independent Director
• Lishan Aklog,
  Director
• Jane Ambler,
  Vice President - Clinical Microbiology
• Dr. Michael Wittekind Ph.D.,
  Consultant
• Dr. Gary Woodnutt,
  Sr. VP of Translational Sciences & Preclinical Devel.
• Dr. Michael Wittekind,
  Consultant
• Natalie Bogdanos J.D.,
  Gen. Counsel, Corp. Sec. & Data Protection Officer
• Isaac Blech,
  Director
• Daniel Couto,
  SVP Manufacturing & Facilities
• Joshua B Muntner,
  SVP Business Development
• Julia P Gregory,
  CEO
• Michael G. Wittekind,
  Chief Scientific Officer
• Steven C Gilman,
  Director
• Lisa Ricciardi,
  Director
• Fosun Pharmaceutical (Group...,
  10% owner
• Industrial Co., Ltd Fosun,
  10% owner
• David B. Huang,
  Chief Medical Officer
• Shengda Zan,
  Director
• Barry J. Kappel,
  SVP Business Development
• David A Scheinberg,
  Director
• W Moody Revocable Trust Ernest,
  10% owner
• Jane F Barlow,
  Director